ES8601703A1 - Un metodo de produccion de una preparacion de proteina a-igg - Google Patents

Un metodo de produccion de una preparacion de proteina a-igg

Info

Publication number
ES8601703A1
ES8601703A1 ES528121A ES528121A ES8601703A1 ES 8601703 A1 ES8601703 A1 ES 8601703A1 ES 528121 A ES528121 A ES 528121A ES 528121 A ES528121 A ES 528121A ES 8601703 A1 ES8601703 A1 ES 8601703A1
Authority
ES
Spain
Prior art keywords
plasma
tumor
prepared
compositions
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES528121A
Other languages
English (en)
Other versions
ES528121A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of ES528121A0 publication Critical patent/ES528121A0/es
Publication of ES8601703A1 publication Critical patent/ES8601703A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO DE PRODUCCION DE COMPOSICIONES DE PROTEINA A-IGG, QUE TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DEL CANCER COMO LINFOMAS Y TUMORES SOLIDOS. CONSISTE EN EL AISLAMIENTO DE PROTEINA A-IGG DE UN PLASMA NORMAL O DE PORTADORES DE TUMORES, DESPUES DE SOMETERLO A PERFUSION SOBRE PROTEINA A DE STAPHYLOCOCCUS AUREUS INMOVILIZADA MEDIANTE PRECIPITACION DEL COMPLEJO DE PROTEINA A-IGG DEL PLASMA PERFUNDIDO.
ES528121A 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de proteina a-igg Expired ES8601703A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36643682A 1982-04-07 1982-04-07
US47236283A 1983-03-11 1983-03-11

Publications (2)

Publication Number Publication Date
ES528121A0 ES528121A0 (es) 1985-11-01
ES8601703A1 true ES8601703A1 (es) 1985-11-01

Family

ID=27003359

Family Applications (5)

Application Number Title Priority Date Filing Date
ES521279A Expired ES8405621A1 (es) 1982-04-07 1983-04-06 Una inmunopreparacion tumoral.
ES528120A Granted ES528120A0 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de plasma activada con zymosan
ES528118A Expired ES8503953A1 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de inmunoglobulina tumoral
ES528119A Granted ES528119A0 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de proteina a-igg
ES528121A Expired ES8601703A1 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de proteina a-igg

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES521279A Expired ES8405621A1 (es) 1982-04-07 1983-04-06 Una inmunopreparacion tumoral.
ES528120A Granted ES528120A0 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de plasma activada con zymosan
ES528118A Expired ES8503953A1 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de inmunoglobulina tumoral
ES528119A Granted ES528119A0 (es) 1982-04-07 1983-12-16 Un metodo de produccion de una preparacion de proteina a-igg

Country Status (13)

Country Link
EP (1) EP0091784B1 (es)
AU (2) AU569467B2 (es)
CA (1) CA1230555A (es)
DE (1) DE3374756D1 (es)
DK (1) DK154283A (es)
ES (5) ES8405621A1 (es)
FI (1) FI831169A7 (es)
GB (2) GB2119803B (es)
GR (1) GR78514B (es)
NO (5) NO831223L (es)
PT (1) PT76505B (es)
RO (3) RO86661A (es)
ZW (1) ZW7583A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2161813B (en) * 1984-07-20 1988-07-13 Michiko Koga Anti-tumor agent
GB9013872D0 (en) * 1990-06-21 1990-08-15 Inst Tecnologico Y Cientifico Use of protein a and polypeptide components thereof in the treatment of tumours
EP0694066A4 (en) * 1993-04-08 1997-01-29 Univ Texas GONOCOCCAL INFECTION MODEL
GB2422311A (en) * 2005-01-20 2006-07-26 Martin Lister Treatment of blood to cure disease
DE102005012594A1 (de) 2005-03-18 2006-09-21 Bayer Technology Services Gmbh Elektrofiltrationsverfahren
SG176064A1 (en) * 2009-05-14 2011-12-29 Oatmeal Biotechnologies Group L L C Platform technologies for spontaneously occurring diseases
EP3426265B1 (en) * 2016-04-28 2021-09-22 Alkahest, Inc. Plasma fractions as therapy for tumor growth and progression
IL304946A (en) 2016-08-18 2023-10-01 Alkahest Inc Blood plasma fractions as a treatment for cognitive disorders associated with aging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US4146603A (en) * 1977-02-18 1979-03-27 Research Corporation Tumor specific glycoproteins and method for detecting tumorigenic cancers
FI791551A7 (fi) * 1978-05-17 1981-01-01 As Alfred Benzon Puhdistettu syöpäassosioitunut proteiini.

Also Published As

Publication number Publication date
NO831223L (no) 1983-10-10
AU1560088A (en) 1988-10-27
RO89496A (ro) 1986-06-30
AU1286583A (en) 1983-10-13
NO841495L (no) 1983-10-10
RO89498A (ro) 1986-06-30
AU569467B2 (en) 1988-02-04
EP0091784A2 (en) 1983-10-19
GB8510892D0 (en) 1985-06-05
ES528118A0 (es) 1985-04-16
NO841496L (no) 1983-10-10
ES8503954A1 (es) 1985-04-16
ES8503950A1 (es) 1985-04-16
ES528121A0 (es) 1985-11-01
RO86661B (ro) 1985-03-01
FI831169L (fi) 1983-10-08
DK154283A (da) 1983-10-08
PT76505A (en) 1983-05-01
GB2119803B (en) 1986-09-03
GR78514B (es) 1984-09-27
NO841497L (no) 1983-10-10
GB2163164A (en) 1986-02-19
FI831169A7 (fi) 1983-10-08
ES8503953A1 (es) 1985-04-16
PT76505B (en) 1986-05-05
GB2119803A (en) 1983-11-23
DK154283D0 (da) 1983-04-07
FI831169A0 (fi) 1983-04-06
ES528119A0 (es) 1985-04-16
EP0091784A3 (en) 1984-07-11
ES521279A0 (es) 1984-06-16
ZW7583A1 (en) 1983-06-29
CA1230555A (en) 1987-12-22
ES528120A0 (es) 1985-04-16
DE3374756D1 (en) 1988-01-14
ES8405621A1 (es) 1984-06-16
NO841498L (no) 1983-10-10
RO86661A (ro) 1986-07-30
GB2163164B (en) 1986-09-03
GB8309348D0 (en) 1983-05-11
EP0091784B1 (en) 1987-12-02

Similar Documents

Publication Publication Date Title
FI943750A0 (fi) Menetelmä nekroositekijän valmistamiseksi
ES8103976A1 (es) Un metodo de producir proteinas de interferon humano de for-ma le
ES414823A1 (es) Metodo para mejorar el rendimiento de un factor anti-hemo- filico obtenido a partir de plasma sanguineo y de fraccionesde plasma.
ATE22562T1 (de) 6-substituierte s-triazolo(3,4-a)phthalazinderivate.
NO880705L (no) Fremgangsmaate til fremstilling av makromolekylare platinaforbindelser med virkning mot kreft.
CA1208130A (en) ULTRAPURIFICATION OF FACTOR VIII
SE8303211D0 (sv) Rena teichomycin a?712 singelfaktorer 1,2,3,4 och 5 och sett for deras framstellning
NO173390C (no) Analogifremgangsm}te for fremstilling av terapeutisk virksomme 1,2-bis(aminometyl)-cyklobutan-platinakomplekser
IE830934L (en) 1,8-diaza-and 1,5,8-triazanaphthalene derivatives
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
MY105946A (en) Antagonists of gm-csf derived from the carboxyl terminus.
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
ES8405621A1 (es) Una inmunopreparacion tumoral.
Dahl et al. Separation of antiviral activity of human interferon from cell growth inhibitory effect
FR2487642B2 (fr) Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions
ES8502998A1 (es) Procedimiento para la preparacion de nuevas b-carbolinas substituidas.
DK292090A (da) Fremgangsmaade til fremstilling af et antithrombin iii-koncentrat
SE8004088L (sv) Nya substituerade 3-fenoxi-l-alkoxikarbonylalkylamino-propanol-2-er med beta-receptorblockerande egenskaper samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma och metod att ...
ATE76579T1 (de) Interferon-zusammensetzungen.
GB1188519A (en) Method for the Purification of Lipopolysaccharides
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
DE3168876D1 (en) Alpha,beta-dihydropolyprenyl derivatives for treating liver diseases
NO162212C (no) Mykoherbicidkonsentrat, herbicid middel og anvendelse derav.
JPS5756426A (en) Novel salt and manufacture
BG42676A3 (en) Method for preparang derivatives of 6- aminoalkyl- penicillanic acid